The Role of the Immune System in Huntington’s Disease
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
Huntington’s disease (HD) is characterized by a progressive course of disease until death 15–20 years after the first symptoms occur and is caused by a mutation with expanded CAG repeats in the huntingtin (htt) protein. Mutant htt (mhtt) in the striatum is assumed to be the main reason for neurodegeneration. Knowledge about pathophysiology has rapidly improved discussing influences of excitotoxicity, mitochondrial damage, free radicals, and inflammatory mechanisms. Both innate and adaptive immune systems may play an important role in HD. Activation of microglia with expression of proinflammatory cytokines, impaired migration of macrophages, and deposition of complement factors in the striatum indicate an activation of the innate immune system. As part of the adaptive immune system, dendritic cells (DCs) prime T-cell responses secreting inflammatory mediators. In HD, DCs may contain mhtt which brings the adaptive immune system into the focus of interest. These data underline an increasing interest in the peripheral immune system for pathomechanisms of HD. It is still unclear if neuroinflammation is a reactive process or if there is an active influence on disease progression. Further understanding the influence of inflammation in HD using mouse models may open various avenues for promising therapeutic approaches aiming at slowing disease progression or forestalling onset of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“several studies have indicated that mutated HTT has an important impact on microglia and neuroinflammation during HD pathogenesis (163).”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [163]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366 · cited 1×
“Huntington’s disease (HD) is an autosomal dominantly inherited disorder with a trinucleotide CAG repeat expansion ≥36 in the exon 1 of the HD gene located on chromosome 4 [1].”
BackgroundM-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287 · cited 1×
“More recent findings further refined this concept and indicate that macrophages can be differentiated into M1 and M2 subtypes [53, 56].”
BackgroundMangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Development of Monocytes, Macrophages, and Dendritic Cells
Geissmann, F., Manz, M. G., Jung, S., Sieweke, M. H., Merad, M., & Ley, K. (2010) · Science · doi:10.1126/science.1178331 · Cited by 3,049
Alternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 1×
“These cytokines inhibit macrophage activation but induce antibody production resulting in resolution of inflammation through endocytic clearance and trophic factor synthesis [57].”
BackgroundMellman, I., & Steinman, R. M. (2001) · Cell · doi:10.1016/s0092-8674(01)00449-4 · Cited by 2,237
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Cited by
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253
“[65] Ellrichmann G, Reick C, Saft C, Linker RA.”
BackgroundMicroglial M1/M2 polarization and metabolic states
Orihuela, R., McPherson, C. A., & Harry, G. J. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13139 · Cited by 2,070
“, 2013; Moehle and West, 2014), Huntington disease (Ellrichmann et al., 2013; Crotti et al., 2014), amyotrophic lateral sclerosis (Evans et al.”
BackgroundBates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
The blood-brain barrier in aging and neurodegeneration
Knox, E. G., Aburto, M. R., Clarke, G., Cryan, J. F., & O’Driscoll, C. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01511-z · Cited by 738
Targeting Huntingtin Expression in Patients with Huntington’s Disease
Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900907 · Cited by 708
Self-citationInflammation in neurodegenerative diseases—An update
Amor, S., Peferoen, L. A. N., Vogel, D. Y. S., Breur, M., van der Valk, P., Baker, D., & van Noort, J. M. (2014) · Immunology · doi:10.1111/imm.12233 · Cited by 550
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
microRNA dysregulation in neurodegenerative diseases: A systematic review
Juźwik, C. A., S. Drake, S., Zhang, Y., Paradis-Isler, N., Sylvester, A., Amar-Zifkin, A., Douglas, C., Morquette, B., Moore, C. S., & Fournier, A. E. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101664 · Cited by 426
Autophagy and Microglia: Novel Partners in Neurodegeneration and Aging
Plaza-Zabala, A., Sierra-Torre, V., & Sierra, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030598 · Cited by 323
“Indeed, the peripheral immune system drives demyelination in MS [79], sustains inflammation, or promotes repair depending on context during ischemic damage [144] and may also contribute to late stages of AD, PD, and HD [148,149].”
BackgroundThe Role of Microglia and Astrocytes in Huntington’s Disease
Palpagama, T. H., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00258 · Cited by 239
Labadorf, A., Hoss, A. G., Lagomarsino, V., Latourelle, J. C., Hadzi, T. C., Bregu, J., MacDonald, M. E., Gusella, J. F., Chen, J.-F., Akbarian, S., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143563 · Cited by 189
IDO and Kynurenine Metabolites in Peripheral and CNS Disorders
Huang, Y.-S., Ogbechi, J., Clanchy, F. I., Williams, R. O., & Stone, T. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00388 · Cited by 187
Complement dysregulation in the central nervous system during development and disease
Lee, J. D., Coulthard, L. G., & Woodruff, T. M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101340 · Cited by 128
Riguet, N., Mahul-Mellier, A.-L., Maharjan, N., Burtscher, J., Croisier, M., Knott, G., Hastings, J., Patin, A., Reiterer, V., Farhan, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26684-z · Cited by 118
Neuroimmunology – the past, present and future
Nutma, E., Willison, H. J., Martino, G., & Amor, S. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13279 · Cited by 111
van Buel, E. M., Patas, K., Peters, M., Bosker, F. J., Eisel, U. L. M., & Klein, H. C. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.100 · Cited by 105
Huntington Disease as a Neurodevelopmental Disorder and Early Signs of the Disease in Stem Cells
Wiatr, K., Szlachcic, W. J., Trzeciak, M., Figlerowicz, M., & Figiel, M. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0477-7 · Cited by 103
Ochaba, J., Monteys, A. M., O’Rourke, J. G., Reidling, J. C., Steffan, J. S., Davidson, B. L., & Thompson, L. M. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.016 · Cited by 94
“Several of these cytokines are altered in HD mouse models and human post-mortem tissue, including TNF-a, IL1-b, IL-6, IL-10, and IFNg (Ellrichmann et al., 2013; Silvestroni et al., 2009).”
Jia, H., Wang, Y., Morris, C. D., Jacques, V., Gottesfeld, J. M., Rusche, J. R., & Thomas, E. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152498 · Cited by 94
Ex vivo gene therapy for the treatment of neurological disorders
Gowing, G., Svendsen, S. P., & Svendsen, C. N. (2017) · Progress in brain research · doi:10.1016/bs.pbr.2016.11.003 · Cited by 88
Changing the Face of Kynurenines and Neurotoxicity: Therapeutic Considerations
Bohár, Z., Toldi, J., Fülöp, F., & Vécsei, L. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16059772 · Cited by 87
Inflammation in Huntington's disease: A few new twists on an old tale
Valadão, P. A. C., Almeida‐Santos, A. F., Ferreira-Vieira, T. H., Cordeiro, T. M. E., Teixeira, A. L., Guatimosim, C., & de Miranda, A. S. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577380 · Cited by 85
Sun, Y., Wei, K., Liao, X., Wang, J., Gao, L., & Pang, B. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5580 · Cited by 79
The path to leptomeningeal metastasis
Remšík, J., & Boire, A. A. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00700-y · Cited by 77
Suicidality in Huntington's disease
Hubers, A. A. M., Reedeker, N., Giltay, E. J., Roos, R. A. C., van Duijn, E., & van der Mast, R. C. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.031 · Cited by 76
Fishbein, M., Gafni, M., & Sarne, Y. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23452 · Cited by 75
Microglial response to aging and neuroinflammation in the development of neurodegenerative diseases
Han, T., Xu, Y., Sun, L., Hashimoto, M., & Wei, J. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385845 · Cited by 72
Ligustilide inhibits microglia-mediated proinflammatory cytokines production and inflammatory pain
Zhu, M.-D., Zhao, L., Wang, X., Gao, Y., & Zhang, Z. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2014.10.002 · Cited by 72
Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics
Jia, Q., Li, S., Li, X.-J., & Yin, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1088124 · Cited by 70
“the periphery to the CNS or vice versa (5, 6).”
BackgroundThe microbiota–gut–brain axis in Huntington's disease: pathogenic mechanisms and therapeutic targets
Ekwudo, M. N., Gubert, C., & Hannan, A. J. (2024) · FEBS Journal · doi:10.1111/febs.17102 · Cited by 65
Apelin/APJ system: A novel promising target for neurodegenerative diseases
Luo, H., Han, L., & Xu, J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29001 · Cited by 63
Miller, J. R. C., Lo, K. K., Andre, R., Hensman Moss, D. J., Träger, U., Stone, T. C., Jones, L., Holmans, P., Plagnol, V., & Tabrizi, S. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw142 · Cited by 62
Fluid and imaging biomarkers for Huntington's disease
Zeun, P., Scahill, R. I., Tabrizi, S. J., & Wild, E. J. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.02.004 · Cited by 61
Labadorf, A. T., Choi, S. H., & Myers, R. H. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00430 · Cited by 59
Sabogal-Guáqueta, A. M., Marmolejo-Garza, A., de Pádua, V. P., Eggen, B., Boddeke, E., & Dolga, A. M. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101805 · Cited by 58
Irfan, Z., Khanam, S., Karmakar, V., Firdous, S. M., Khier, B. S. I. A. E., Khan, I., Rehman, M. U., & Khan, A. (2022) · Brain Sciences · doi:10.3390/brainsci12101389 · Cited by 58
A Critical Evaluation of Wet Biomarkers for Huntington’s Disease: Current Status and Ways Forward
Silajdžić, E., & Björkqvist, M. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170273 · Cited by 58
Dong, Y., Dekens, D. W., Deyn, P. P. D., Naudé, P. J. W., & Eisel, U. L. M. (2015) · Antibodies · doi:10.3390/antib4040369 · Cited by 56
Erucic acid, a nutritional PPARδ-ligand may influence Huntington’s disease pathogenesis
Altinoz, M. A., Özpınar, A., Ozpinar, A., & Hacker, E. C. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00500-6 · Cited by 54
Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin
Connolly, C., Magnusson, A., Lu, G., Wagner, P. K., Southwell, A. L., Hayden, M. R., Björkqvist, M., & Leavitt, B. R. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.03.031 · Cited by 51
Dowie, M. J., Grimsey, N. L., Hoffman, T., Faull, R. L. M., & Glass, M. (2014) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2014.06.004 · Cited by 50
Toll-Like Receptor Signaling Pathways: Novel Therapeutic Targets for Cerebrovascular Disorders
Ahmadabad, R. A., Mirzaasgari, Z., Gorji, A., & Ghadiri, M. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116153 · Cited by 50
Kerkis, I., Haddad, M. S., Valverde, C. W., & Glosman, S. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0248-1 · Cited by 49
Romo, L., Ashar-Patel, A., Pfister, E. L., & Aronin, N. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.009 · Cited by 49
Simmons, D. A., James, M. L., Belichenko, N. P., Semaan, S., Condon, C., Kuan, J., Shuhendler, A. J., Miao, Z., Chin, F. T., & Longo, F. M. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy202 · Cited by 47
Kaur, N., Jamwal, S., Deshmukh, R. R., Gauttam, V. K., & Kumar, P. (2015) · Toxicology Reports · doi:10.1016/j.toxrep.2015.08.004 · Cited by 45
Ahmadabad, R. A., Ghadiri, M. K., & Gorji, A. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01785-6 · Cited by 45
The Role of the Immune System in Triplet Repeat Expansion Diseases
Olejniczak, M., Urbanek-Trzeciak, M. O., & Krzyżosiak, W. J. (2015) · Mediators of Inflammation · doi:10.1155/2015/873860 · Cited by 44
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells
Dobson, L., Träger, U., Farmer, R. E., Hayardeny, L., Loupe, P. S., Hayden, M. R., & Tabrizi, S. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13553 · Cited by 43
Immunotherapies in Huntington's disease and α-Synucleinopathies
Fatoba, O., Ohtake, Y., Itokazu, T., & Yamashita, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00337 · Cited by 42
Reilmann, R., Anderson, K. E., Feigin, A., Tabrizi, S. J., Leavitt, B. R., Stout, J. C., Piccini, P. P., Schubert, R., Loupe, P. S., Wickenberg, A. T., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00454-4 · Cited by 42
Self-citationCorey‐Bloom, J., Fischer, R. S., Kim, A., Snell, C. M., Parkin, G. M., Granger, D. A., Granger, S. W., & Thomas, E. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176363 · Cited by 41
Fu, M., Li, C.-L., Lin, H.-L. H., Tsai, S., Lai, Y.-Y., Chang, Y.-F., Cheng, P., Chen, C., & Yang, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137637 · Cited by 40
Lum, P. T., Sekar, M., Seow, L.-J., Shaikh, M. F., Arulsamy, A., Retinasamy, T., Gan, S. H., Gnanaraj, C., Esa, N. M., Ramachawolran, G., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1189957 · Cited by 40
Pramotton, F. M., Spitz, S., & Kamm, R. D. (2024) · Advanced Science · doi:10.1002/advs.202403892 · Cited by 39
Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases
Baidya, F., Bohra, M., Datta, A., Sarmah, D., Shah, B., Jagtap, P., Raut, S., Sarkar, A., Singh, U., Kalia, K., et al. (2021) · Immunology · doi:10.1111/imm.13264 · Cited by 38
Reick, C., Ellrichmann, G., Tsai, T., Lee, D.-H., Wiese, S., Gold, R., Saft, C., & Linker, R. A. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.08.012 · Cited by 38
Self-citationNeuron-immunity communication: mechanism of neuroprotective effects in EGCG
Chen, Y., Liu, Z., & Gong, Y. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2212069 · Cited by 35
Novel candidate blood‐based transcriptional biomarkers of machado‐joseph disease
Raposo, M., Bettencourt, C., Maciel, P., Gao, F., Ramos, A., Kazachkova, N., Vasconcelos, J., Kay, T. T., Rodrigues, A. J., Bettencourt, B. F., et al. (2015) · Movement Disorders · doi:10.1002/mds.26238 · Cited by 35
Quality Control in Huntington’s Disease: a Therapeutic Target
Nand, S., Singh, B. K., Rathore, A. S., Zahra, W., Keswani, C., Birla, H., Singh, S. S., Dilnashin, H., & Singh, S. P. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00087-x · Cited by 35
Identification of contributing genes of Huntington’s disease by machine learning
Cheng, J., Liu, H., Lin, W., & Tsai, F. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-00822-w · Cited by 35
Xu, Y., Jiang, Y., Wang, L., Huang, J., Wen, J., Lv, H., Wu, X., Wan, C., Yu, C., Zhang, W., et al. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00346-z · Cited by 34
Weng, Y., Chang, Y., & Chern, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043443 · Cited by 34
Therapeutic approaches targeting aging and cellular senescence in Huntington's disease
Bhat, A. A., Moglad, E. H. O., Afzal, M., Thapa, R., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., Ali, H., Pant, K., Singh, T. G., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70053 · Cited by 33
Deficiency of Toll-like receptors 2, 3 or 4 extends life expectancy in Huntington’s disease mice
Griffioen, K., Mattson, M. P., & Okun, E. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00508 · Cited by 33
Bondulich, M. K., Fan, Y., Song, Y., Giorgini, F., & Bates, G. P. (2021) · Scientific Reports · doi:10.1038/s41598-021-84858-7 · Cited by 31
Pardo, A. D., Ciaglia, E., Cattaneo, M., Maciag, A. E., Montella, F., Lopardo, V., Ferrario, A., Villa, F., Madonna, M., Amico, E., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02754-w · Cited by 31
Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Török, N., Majláth, Z., Fülöp, F., Toldi, J., & Vécsei, L. (2016) · Current Drug Metabolism · doi:10.2174/1389200217666151222155043 · Cited by 28
Mukherjee, S. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e08518 · Cited by 27
Demethyleneberberine: A possible treatment for Huntington’s disease
Gupta, S., Khan, A., Vishwas, S., Gulati, M., Singh, T. G., Dua, K., Singh, S. K., Najda, A., Sayed, A. A., Almeer, R., et al. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110639 · Cited by 26
Gómez-Jaramillo, L., Cano-Cano, F., González-Montelongo, M. D. C., Campos‐Caro, A., Aguilar‐Diosdado, M., & Arroba, A. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116089 · Cited by 25
Islam, M. R., Jony, M. H., Thufa, G. K., Akash, S., Dhar, P. S., Rahman, M. M., Afroz, T., Ahmed, M., Hemeg, H. A., Rauf, A., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03604-4 · Cited by 25
Bouwens, J. A., van Duijn, E., Cobbaert, C. M., Roos, R. A. C., van der Mast, R. C., & Giltay, E. J. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160213 · Cited by 25
Roussakis, A., Gennaro, M., Gordon, M. F., Reilmann, R., Borowsky, B., Rynkowski, G., Lao–Kaim, N. P., Papoutsou, Z., Savola, J., Hayden, M. R., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad084 · Cited by 24
Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease
Luca, G., Bellezza, I., Arato, I., Pardo, A. D., Mancuso, F., Calvitti, M., Falabella, G., Bartoli, S., Maglione, V., Amico, E., et al. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12569 · Cited by 23
Blood brain barrier inflammation and potential therapeutic role of phytochemicals
Welcome, M. O. (2020) · PharmaNutrition · doi:10.1016/j.phanu.2020.100177 · Cited by 22
Laprairie, R. B., Warford, J. R., Hutchings, S., Robertson, G. S., Kelly, M. E. M., & Denovan‐Wright, E. M. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.12.008 · Cited by 22
Aqel, S., Ahmad, J., Saleh, I., Fathima, A., Thani, A. A. A., Mohamed, W. M. Y., & Shaito, A. A. (2025) · Biology · doi:10.3390/biology14020129 · Cited by 22
PET and MR imaging of neuroinflammation in hepatic encephalopathy
Su, Y. Y., Yang, G. F., Lu, G., Wu, S., & Zhang, L. J. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9633-1 · Cited by 22
Khaboushan, A. S., Moeinafshar, A., Ersi, M. H., Teixeira, A. L., Zolbin, M. M., & Kajbafzadeh, A. M. (2023) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2023.578243 · Cited by 21
Bouwens, J. A., Hubers, A. A. M., van Duijn, E., Cobbaert, C. M., Roos, R. A. C., van der Mast, R. C., & Giltay, E. J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.05.004 · Cited by 19
Laroche, M., Lessard‐Beaudoin, M., Garcia‐Miralles, M., Kreidy, C., Peachey, E., Leavitt, B. R., Pouladi, M. A., & Graham, R. K. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa099 · Cited by 19
Kumar, V., Lee, J. D., Coulson, E. J., & Woodruff, T. M. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15119 · Cited by 19
Inflammatory changes in peripheral organs in the BACHD murine model of Huntington's disease
Valadão, P. A. C., Oliveira, B. D. S., Joviano‐Santos, J. V., Vieira, É. L. M., Rocha, N. P., Teixeira, A. L., Guatimosim, C., & de Miranda, A. S. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116653 · Cited by 18
Huntington’s Disease: Pathogenic Mechanisms and Therapeutic Targets
Wright, D. J., Renoir, T., Gray, L. J., & Hannan, A. J. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_4 · Cited by 18
Labadorf, A. T., Hoss, A. G., Lagomarsino, V. N., Latourelle, J. C., Hadzi, T. C., Bregu, J., MacDonald, M. E., Gusella, J. F., Chen, J., Akbarian, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160295 · Cited by 18
Miller, J. R. C., Träger, U., André, R., & Tabrizi, S. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141793 · Cited by 17
Corey‐Bloom, J., Aikin, A. M., Gutierrez, A. M., Nadhem, J. S., Howell, T. L., & Thomas, E. A. (2017) · Brain Research · doi:10.1016/j.brainres.2017.08.013 · Cited by 17
Neuroinflammation in Huntington's disease: Causes, consequences, and treatment strategies
Blusch, A., & Björkqvist, M. (2025) · Journal of Huntington s Disease · doi:10.1177/18796397251338207 · Cited by 17
Tomaszewska-Zaremba, D., Gajewska, A., & Misztal, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146570 · Cited by 16
Dong, X., & Cong, S. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8410 · Cited by 16
Bellver‐Sanchís, A., Ribalta‐Vilella, M., Irisarri, A., Gehlot, P., Choudhary, B. S., Jana, A., Vyas, V. K., Banerjee, D. R., Pallàs, M., Guerrero, A., et al. (2025) · Medicinal Research Reviews · doi:10.1002/med.22096 · Cited by 14
Goleij, P., Amini, A., Sanaye, P. M., Heidari, M. M., Tabari, M. A. K., Aschner, M., Larsen, D. S., Khan, H., & Daglia, M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01901-z · Cited by 14
Loureiro, S. O., Sidegum, D. S. V., Biasibetti, H., Pereira, M. S. L., de Oliveira, D. L., Pessoa‐Pureur, R., & Wyse, Â. T. D. S. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-9067-0 · Cited by 14
Challenges of Huntington's disease and quest for therapeutic biomarkers
Kotrčová, E., Jarkovská, K., Valeková, I., Žižková, M. (., Motlík, J., Gadher, S. J., & Kovářová, H. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400073 · Cited by 12
Cantero-Téllez, A., Moreno‐Fierros, L., Gutiérrez‐Ospina, G., Santiago-Prieto, A. C., Juárez, I., Rodríguez‐Sosa, M., & Hernández, E. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04356-4 · Cited by 11
Li, N., Li, Y., Huang, J., Zhang, P., Tong, J., Song, C., Cui, Y., Tan, S., Wang, Z., Yang, F., et al. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136581 · Cited by 11
Bridging the Gap: The Neuro-immune Axis as a Key Player in Neurodegenerative Disorders
Liu, T., Wu, H., & Wei, J. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01439-8 · Cited by 10
Comparing HD knockin pigs and mice reveals the pathological role of IL-17
Jia, Q., Bai, D., Zheng, X., Zhu, L., Ou, K., Wang, X., Tong, H., Zhang, Y., Wang, J., Zeng, J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113443 · Cited by 9
Metadata
- Authors
- Ellrichmann, G., Reick, C., Saft, C., & Linker, R. A.
- Affiliations
- St. Josef-Hospital (DE)
- Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44791 Bochum, Germany
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Corresponding author
- Ellrichmann, Gisa
- Venue
- Clinical and Developmental Immunology
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-11
- ISSN
- 1740-2522 (ISSN-L)
- 1740-2530
- PMC
- PMC3727178
- OpenAlex
- W2147983580
- Cited by
- 155
- References
- 106
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 13 · 2023: 13 · 2022: 7 · 2021: 14 · 2020: 15 · 2019: 11 · 2018: 7 · 2017: 12 · 2016: 12 · 2015: 17 · 2014: 9 · 2013: 2
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Clinical and Developmental Immunology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Teva Pharmaceutical Industries
- Cure Huntington’s Disease Initiative
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Keywords
- Huntington's disease, neuroinflammation, innate immune system, adaptive immunity, microglial activation, macrophage migration, complement deposition, dendritic cells, T cell response, mutant huntingtin, striatum, neurodegeneration, CAG repeat expansion, peripheral immune system
- MeSH terms
- Animals, Humans, Huntington Disease, Immune System, Immunity, Innate, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.